Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

3.

The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells.

Satoh T, Hoshikawa Y, Satoh Y, Kurata T, Sairenji T.

Virus Genes. 1999;18(1):57-64.

PMID:
10334038
4.
5.

Epstein-Barr virus latently infected cells are selectively deleted in simulated-microgravity cultures.

Long JP, Hughes JH.

In Vitro Cell Dev Biol Anim. 2001 Apr;37(4):223-30.

PMID:
11409687
6.

An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.

Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, Longnecker R, Kieff E.

J Virol. 1999 Dec;73(12):10525-30.

7.

Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells.

Fukuda M, Satoh TA, Takanashi M, Hirai K, Ohnishi E, Sairenji T.

Viral Immunol. 2000;13(2):215-29.

PMID:
10893001
8.

Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.

De Leo A, Arena G, Stecca C, Raciti M, Mattia E.

Mol Cancer Res. 2011 Oct;9(10):1346-55. doi: 10.1158/1541-7786.MCR-11-0145. Epub 2011 Aug 19.

9.

An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells.

Nikitin PA, Yan CM, Forte E, Bocedi A, Tourigny JP, White RE, Allday MJ, Patel A, Dave SS, Kim W, Hu K, Guo J, Tainter D, Rusyn E, Luftig MA.

Cell Host Microbe. 2010 Dec 16;8(6):510-22. doi: 10.1016/j.chom.2010.11.004.

10.
11.

PKC theta and p38 MAPK activate the EBV lytic cycle through autophagy induction.

Gonnella R, Granato M, Farina A, Santarelli R, Faggioni A, Cirone M.

Biochim Biophys Acta. 2015 Jul;1853(7):1586-95. doi: 10.1016/j.bbamcr.2015.03.011. Epub 2015 Mar 27.

12.

Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Lai KY, Chou YC, Lin JH, Liu Y, Lin KM, Doong SL, Chen MR, Yeh TH, Lin SJ, Tsai CH.

J Virol. 2015 Jun;89(11):5968-80. doi: 10.1128/JVI.00168-15. Epub 2015 Mar 25.

13.

Epstein-Barr virus signal transduction and B-lymphocyte growth transformation.

Izumi KM.

Prog Mol Subcell Biol. 2004;36:269-88. Review.

PMID:
15171616
14.
15.

Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.

Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM, Kieff E.

J Virol. 2004 Apr;78(8):4108-19.

16.

To be or not IIb: a multi-step process for Epstein-Barr virus latency establishment and consequences for B cell tumorigenesis.

Price AM, Luftig MA.

PLoS Pathog. 2015 Mar 19;11(3):e1004656. doi: 10.1371/journal.ppat.1004656. eCollection 2015 Mar. Review. No abstract available.

17.

Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade.

Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W.

EMBO J. 1997 Nov 3;16(21):6478-85.

18.

Shutoff of BZLF1 gene expression is necessary for immortalization of primary B cells by Epstein-Barr virus.

Yu X, McCarthy PJ, Wang Z, Gorlen DA, Mertz JE.

J Virol. 2012 Aug;86(15):8086-96. doi: 10.1128/JVI.00234-12. Epub 2012 May 23.

19.

c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08. Epub 2009 Mar 4.

Supplemental Content

Support Center